The Proof with Simon Hill

Lowering cholesterol with medicine | Dr Thomas Dayspring and Dr Dan Soffer

85 snips
Sep 1, 2025
Dr. Thomas Dayspring, a lipidology expert, and Dr. Dan Soffer, a cardiologist specializing in preventive cardiology, dive into the world of lipid-lowering therapies. They discuss the effectiveness of statins, ezetimibe, and newer drugs like bempedoic acid. The conversation highlights who benefits most from these treatments and the importance of personalized care. Historical clinical trials radically transformed our understanding of cholesterol management, revealing how early intervention can significantly reduce cardiovascular risk. They also touch on the challenges of including women in clinical trials.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
ANECDOTE

Clinician’s Personal Statin Myopathy Story

  • Thomas Dayspring describes personal severe statin myopathy and myoglobinuria that forced him off statins.
  • He then experienced similar muscle symptoms with ezetimibe, highlighting variable idiosyncratic intolerance.
ADVICE

Start With Generic Statin ± Ezetimibe

  • Start treatment with generic statins and ezetimibe first because they are inexpensive and widely accessible.
  • Reserve costlier options (PCSK9 inhibitors, bempedoic acid) for when lower-cost drugs can't reach goals or are not tolerated.
INSIGHT

Short Trials Underestimate Lifetime Benefit

  • Short trial absolute risk reductions understate lifetime benefit; Mendelian data show much larger proportional gains from lifelong lower LDL.
  • 'Lower for longer' produces greater cumulative risk reduction than short RCT windows suggest.
Get the Snipd Podcast app to discover more snips from this episode
Get the app